|
Official Course
Description: MCCCD Approval: 2-28-06 |
|||
|
DMI273
2006 Summer I – 2009 Sumer
II |
LEC |
3.0 Credit(s) |
3.0 Period(s) |
|
Nuclear
Medicine Imaging III |
|||
|
Nuclear
medicine imaging studies of the central nervous system (CNS) hematological
and in vitro nuclear medicine and immune system. Review of related anatomy,
physiology and pathology. CNS imaging studies including cerebral vascular
flow, planar brain imaging, functional brain single photon emission computed
tomography (SPECT), brain tumor imaging, and cerebral spinal fluid studies.
Immune system imaging studies including radiolabeled
white blood cell studies, gallium, breast, and sentinel node imaging, radioimmunoscintigraphy, lymphoscintigraphy
and Iodine-131 whole body imaging. Introduction to radionuclide therapy
including intracavitary palliation, bone marrow
palliation, palliation of metastatic bone pain and radiolabeled
antibody therapies. Hematological and in vitro studies to include bone marrow
imaging, Schillings test, plasma volume, red cell mass, total blood volume,
T- cell survival, splenic imaging and radioassay. Prerequisites: DMI271 or permission of
Nuclear Medicine Technology program director. |
|||
Go to Competencies Go to Outline
|
MCCCD
Official Course Competencies: |
|
|
|
|
|
DMI273 2006
Summer I – 2009 Sumer II |
Nuclear Medicine Imaging III |
|
1.
|
Discuss the gross anatomy and physiology of the central
nervous, immune and hematological systems as they relate to nuclear medicine
studies. (I, VIII, XVII) |
|
2.
|
Describe the characteristics and causes of common
pathologies of the central nervous, hematological and immune systems related
to nuclear medicine procedures including susceptible populations and
potential treatments. (II, IX) |
|
3.
|
List the indications for performing selected CNS ,
hematological and in vitro studies imaging studies. (III-VII) |
|
4.
|
List dose and route of administration, biorouting
and dosimetry of each radiopharmaceutical used for
selected CNS, hematological and immune system imaging studies. (III-VII) |
|
5.
|
Discuss the possible adverse reactions and
contraindications for selected CNS hematological and in vitro studies imaging
studies. (III-VII) |
|
6.
|
Describe patient preparation for selected CNS
hematological and in vitro studies imaging studies. (III-VII, X-XV, XVIII-
XXIII) |
|
7.
|
Describe equipment and basic procedures and processing
utilized in selected CNS hematological and in vitro studies imaging studies.
(III-VII) |
|
8.
|
Recognize normal, normal variants, abnormal findings, and
artifacts on CNS hematological and in vitro studies imaging studies.
(III-VII) |
|
9.
|
Discuss the diagnostic and prognostic value of selected
CNS hematological and in vitro studies imaging studies. (III-VII, X-XV,
XVIII-XXIII) |
|
10.
|
Discuss the interventions and additional procedures that
may be added to a basic functional brain SPECT study. (V) |
|
11.
|
List the indications for performing selected immune system
imaging studies. (X-XV, XVI-XXIII) |
|
12.
|
Discuss why a nuclear medicine study would be preferable
to or compliment other diagnostic modalities in various cases. (X-XV,
XVI-XXIII) |
|
13.
|
Describe the radiopharmaceuticals used for selected immune
system imaging studies including the physical and chemical properties, biorouting dose preparation, and route and method of
administration. (X-XV, XVI-XXIII) |
|
14.
|
Specify the dose range for selected immune system imaging
studies and the resulting radiation doses to various organs and tissues.
(X-XV, XVI-XXIII) |
|
15.
|
Describe patient preparation for selected immune system
imaging studies. (X-XV, XVI-XXIII) |
|
16.
|
Describe the procedures for selected immune system imaging
studies including equipment, protocol, dose, administration technique,
administration-to-acquisition times, acquisition parameters, standard
positioning, special imaging adaptations, data processing and potential
pitfalls. (X-XV, XVI-XXIII) |
|
17.
|
Recognize the normal distribution, normal variants and
various artifacts seen on selected immune system imaging studies and printed
images. (X-XV, XVI-XXIII) |
|
18.
|
Describe dose and standard preparation for a Schilling
test. (XXIV) |
|
19.
|
Calculate Schilling test results, plasma volume, red cell
mass, total blood volume, and degree of red cell sequestration for selected
hematological studies. (XXIV- XXVIII) |
|
20.
|
Describe the preparation of the standard used to calculate
a plasma volume. (XXV) |
|
21.
|
Describe the procedures for plasma volume study including
equipment, protocol, dose, administration technique, sample collection and
processing, data processing and potential pitfalls. (XXV) |
|
22.
|
Describe the procedure for correcting for a vascular leakage
when performing a plasma volume determination. (XXV) |
|
23.
|
Determine the normal range of plasma volume values red
cell mass for a specific patient. (XXV, XXVI) |
|
24.
|
State the rationale for using the hematocrit
correction factor when calculating the red cell mass. (XXV) |
|
25.
|
Describe standard preparation and method for tagging red
blood cells for red cell sequestration determination including the function
of the components used in the process. (XXVIII) |
|
26.
|
Describe the characteristics of a good assay for detecting
minute quantities of substances in the blood. (XXIX) |
Go to Description Go to top of
Competencies
|
MCCCD
Official Course Outline: |
||
|
|
||
|
DMI273 2006
Summer I – 2009 Sumer II |
Nuclear Medicine Imaging III |
|
|
||
|
I. Review of central
nervous system (CNS) anatomy and physiology A. Gross anatomy and
function B. Cellular anatomy and
function C. Blood Flow D. Cerebral spinal fluid
production and flow II. CNS Pathology:
Characteristics, Causes, Population, and Treatment A. Inflammatory disease of
the brain B. Alzheimer's disease C. Parkinson's disease D. Hematoma and contusion
of the brain E. Brain attack (ischemia
and infarct due to cerebral vascular disease) 1. Transient ischemic
attack 2. Stroke 3. Thrombus and embolus 4. Aneurysm and hemorrhage F. Tumors G. Epilepsy H. Traumatic brain injury I. Brian death J. Neurological and
psychiatric diseases K. Communicating
hydrocephalus L. Non-communicating
hydrocephalus M. Otorrhea
N. Rhinorrhea
III. Cerebral vascular flow
A. Indications B. Radiopharmaceuticals 1. Tracers a. Tc-99m sodium pertechnetate b. Tc-99m DTPA (pentetate) 2. Dose range and route of
administration 3. Biorouting
a. uptake b. distribution c. excretion 4. Dosimetry
C. Contraindications and
adverse reactions 1. Interfering studies 2. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Image formatting 6. Pitfalls G. Interpretation of images
1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis IV. Planar Brain Imaging A. Indications B. Radiopharmaceuticals 1. Tracers a. Tc-99m sodium pertechnetate b. Tc-99m DTPA (pentetate) 2. Dose range and route of
administration 3. Biorouting
a. uptake b. distribution c. excretion 4. Dosimetry
C. Contraindications and
adverse reactions 1. Interfering studies 2. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Image formatting 6. Pitfalls G. Interpretation of images
1. Normal 2. Normal vs Abnormal 3. Artifacts 4. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis V. Functional Brain SPECT A. Indications B. Radiopharmaceuticals 1. Historical tracer 2. Current tracers a. Tc-99m HMPAO (exametazime) b. Tc-99m ECD (bicisate) 3. Dose range and route of
administration 4. Biorouting
a. uptake b. distribution c. excretion 5. Dosimetry
C. Contraindications and
adverse reactions 1. Physical conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimator 3. computer 4. ancillary equipment 5. monitoring devices F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Data processing
(including co-registration and 3-dimensional volumetric display) 6. Image formatting 7. Pitfalls G. Interventions in
procedures 1. Vasodilators (acetazolamide) 2. Pyschological
stress studies 3. Sensory stimulation
studies H. Interpretation of images
and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis VI. Brain tumor imaging A. Indications B. Radiopharmaceuticals 1. Tracers 2. Dose range and route of
administration 3. Biorouting
a. uptake b. distribution c. excretion 4. Dosimetry
C. Contraindications and
adverse reactions 1. Interfering studies 2. Adverse reactions D. Patient preparation E. Equipment 1. Camera 2. Collimators 3. Ancillary equipment F. Basic procedure and
processing 1. Protocols 2. Radiopharmaceutical
administration and technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Data processing 6. Image formatting 7. Pitfalls G. Interpretation of images
and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis VII. Cerebral Spinal Fluid
(CSF) Studies A. Cisternography
1. Indications 2. Radiopharmaceuticals a. Historical tracer b. Current tracer:
Indium-111 (In-111) DTPA (pentetate) c. Dose range and route of
administration d. Biorouting
(1). uptake (2). distribution (3). excretion e. Dosimetry
3. Contraindications and
adverse reactions a. physical and pathologic
conditions b. interfering studies c. precautions d. adverse reactions 4. Patient preparation 5. Equipment a. camera b. collimators 6. Basic procedure and
processing a. protocols b. dose range and
administration technique c. acquisition parameters d. positioning and views,
including adaptations e. image formatting f. pitfalls 7. Interpretation of images
a. normal b. normal variants c. abnormal d. artifacts e. Diagnostic/Prognostic
Value of the Study (1). outcomes (2). treatment decisions (3). prognostic risk
factors based on diagnosis B. CSF Leak Study 1. Indications 2. Radiopharmaceuticals a. Historical tracer b. Current tracer (1). In-111 Diethylenetriaminepentaacetate (DTPA) (2). Tc-99m DTPA c. Dose range and route of
administration d. Biorouting
3. uptake 4. distribution 5. excretion a. Dosimetry
6. Contraindications and
adverse reactions a. physical and pathologic
conditions b. interfering studies c. precautions d. adverse reactions 7. Patient preparation 8. Equipment a. camera b. collimators c. well counter 9. Basic procedure and
processing a. protocols b. dose range and
administration technique c. acquisition parameters d. positioning and views,
including adaptations e. data processing
(including counting of pledgets in well counters) f. image formatting g. pitfalls 10. Interpretation of
images and data a. normal b. normal variants c. abnormal d. artifacts e. Diagnostic/Prognostic
Value of the Study (1). outcomes (2). treatment decisions (3). prognostic risk
factors based on diagnosis C. cerebrospinal fluid
(CSF) Shunt Patency 1. Indications 2. Radiopharmaceuticals a. Historical tracer b. Current tracer (1). In-111 DTPA (2). Tc-99m DTPA 3. Contraindications and
adverse reactions a. interfering studies b. precautions c. adverse reactions 4. Patient preparation 5. Equipment a. camera b. collimators 6. Basic procedure and
processing a. protocols b. dose range and
administration technique c. acquisition parameters d. positioning and views,
including adaptations e. image formatting f. pitfalls 7. Interpretation of images
a. normal b. normal variants c. abnormal d. artifacts e. Diagnostic/Prognostic
Value of the Study (1). outcomes (2). treatment decisions (3). prognostic risk
factors based on diagnosis VIII. Oncology/Inflammation
A. Review of anatomy and
physiology 1. Immune process 2. Lymph node distribution 3. Receptor physiology 4. Inflammatory processes 5. Malignant processes IX. Pathology:
Characteristics, Causes, Population, and Treatment A. Inflammatory diseases B. Radiopharmaceuticals 1. Tracers a. In-111 oxine tagged white blood cells b. Tc-99m hexametazime (HMPAO) tagged white blood cells 2. Dose range and route of
administration 3. Biorouting
a. uptake b. distribution c. excretion 4. Dosimetry
C. Contraindications and
adverse reactions 1. Physical or pathological
conditions 2. Interfering studies 3. Precautions 4. Adverse Reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer 4. laboratory equipment for
tagging process F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Data processing 6. Image formatting 7. Pitfalls G. Interpretation of images
1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis X. Radiolabeled
White Blood Cell Studies A. Indications B. Radiopharmaceuticals 1. Tracers a. In-111 oxine tagged white blood cells b. Tc-99m hexametazime (HMPAO) tagged white blood cells c. (NeutroSpec)
fanolesomab Tc99m 2. Dose range and route of
administration 3. Biorouting
a. uptake b. distribution c. excretion 4. Dosimetry
C. Contraindications and
adverse reactions 1. Physical or pathological
conditions 2. Interfering studies 3. Precautions 4. Adverse Reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer 4. laboratory equipment for
tagging process F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Data processing 6. Image formatting 7. Pitfalls G. Interpretation of images
1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XI. Gallium Imaging A. Indications B. Radiopharmaceutical 1. Gallium-67 (Ga-67)
citrate 2. Dose range and route of
administration 3. Biorouting
a. uptake b. distribution c. excretion 4. Dosimetry
C. Contraindications and
adverse reactions 1. Physical conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse Reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Data processing 6. Image formatting 7. Pitfalls G. Interpretation of images
1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XII. Antibody Receptor
Imaging A. Indications B. Radiopharmaceuticals 1. Tracers a. In-111 satumomab penetide (for colon
and ovarian cancer) b. Tc-99m arcitumomab (for colon cancer c. In-111 capromab pendetide (for
prostate cancer) d. other approval
radiopharmaceuticals 2. Physical characteristics
a. whole antibody b. antibody fragments c. designer antibodies 3. Dose range and route of
administration 4. Biorouting
a. uptake b. distribution c. excretion 5. Dosimetry
C. Contraindications and
adverse reactions 1. Physical or pathologic
conditions 2. Interfering studies 3. Precautions 4. Adverse Reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Data processing 6. Image formatting 7. Pitfalls G. Interpretation 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis 6. Abnormal 7. Artifacts 8. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XIII. Breast Imaging (Scintimammography) A. Indications B. Radiopharmaceutical 1. Tc-99m sestamibi 2. Dose range and route of administration
3. Biorouting
a. uptake b. distribution c. excretion 4. Dosimetry
C. Contraindications and
adverse reactions 1. Physical conditions 2. Interfering studies 3. Precautions 4. Adverse Reactions D. Patient preparation E. Equipment 1. camera 2. collimator 3. computer 4. palette F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Image formatting 6. Pitfalls G. Interpretation of images
1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XIV. Sentinel Node Imaging A. Indications B. Radiopharmaceuticals 1. Tracers a. Tc-99m sulfur colloid 2. Dose range and route of
administration 3. Biorouting
a. uptake b. distribution c. excretion 4. Dosimetry
C. Contraindications and
adverse reactions 1. Physical conditions 2. Interfering studies 3. Precautions 4. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Image formatting 6. Pitfalls G. Interpretation data 1. Normal 2. Normal variant 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XV. Lymphoscintigraphy
A. Indications
Radiopharmaceutical 1. Tc-99m sulfur colloid 2. Dose range and route of
administration 3. Biorouting
a. uptake b. distribution c. excretion 4. Dosimetry
B. Contraindications 1. Physical conditions 2. Interfering studies 3. Precautions 4. Adverse reactions C. Patient preparation D. Equipment 1. camera 2. collimators 3. computer E. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Image formatting 6. Pitfalls F. Interpretation of data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XVI. Review of immune
system anatomy and physiology A. Malignant processes B. Metastatic processes XVII. Pathology A. Body cavities 1. malignancies 2. cavitary
effusions B. Bone and bone marrow 1. leukemia 2. polycythemia
vera 3. metastatic bone cancer XVIII. Intracavitary
Palliation A. Indications B. Radiopharmaceuticals 1. Phosphorus-32 (P-32)
chromic phosphate 2. Dose range and route of
administration 3. Biorouting
a. uptake b. distribution c. excretion 4. Dosimetry
C. Contraindications and
adverse reactions 1. Physical and pathologic
conditions 2. Precautions 3. Adverse Reactions D. Patient preparation
(including consent) E. Equipment (for detection
of tracer distribution) 1. camera 2. collimators 3. computer F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Image formatting 6. Pitfalls 7. Interpretation 8. Evaluation of tracer
distribution 9. Prognostic Value
(outcome) XIX. Bone Marrow Palliation
A. Indications B. Radiopharmaceuticals 1. P-32 sodium chromate 2. Dose range and route of
administration 3. Biorouting
a. uptake b. distribution c. excretion 4. Dosimetry
C. Contraindications and
adverse reactions 1. Physical and pathologic
conditions 2. Precautions 3. Adverse Reactions D. Special radiation safety
considerations and regulations E. Patient preparation
(including consent) F. Basic procedures 1. Protocols 2. Dose range and
administration technique 3. Pitfalls G. Prognostic Value 1. outcomes 2. treatments decisions 3. prognostic risk factors
based on diagnosis XX. Palliation of
Metastatic Bone Pain A. Indications B. Radiopharmaceuticals 1. Tracers a. Strontium-89 (Sr-89)
chloride b. Samarium-153 (Sm-153)
EDTMP 2. Dose and route of
administration 3. Biorouting
a. uptake b. distribution c. excretion C. Contraindications and
adverse reactions 1. Physical and pathologic
conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse Reactions D. Special radiation safety
considerations and regulations E. Patient preparation
(including consent) F. Equipment (if
applicable) 1. camera 2. collimators 3. computer G. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Image formatting 6. Pitfalls H. Interpretation of Images
(if applicable) 1. Distribution 2. Artifacts 3. Diagnostic/Prognostic
Value of Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XXI. Hematological and In
Vitro Procedures - Review of anatomy and physiology A. Gross anatomy and
function B. Cellular anatomy and
function C. Life cycle of red and
white blood cells D. Vitamin B12 absorption
and biorouting XXII. Review of
Hematological Pathology A. Anemias
relevant to nuclear medicine studies 1. Pernicious anemia 2. Megaloblastic
anemia (B12 or folic acid deficiency) 3. Thalassemia
4. Sickle cell anemia 5. Autoimmune hemolytic
anemia 6. Traumatic cardiac
hemolytic anemia 7. Hypersplenism
B. Malabsorption
syndrome C. Polycythemia
vera D. Bone marrow cancers E. Bone marrow necrosis and
infarct XXIII. Bone Marrow Imaging A. Indications B. Radiopharmaceutical 1. Tc-99m sulfur colloid 2. Dose range and route of
administration 3. Biorouting
a. uptake b. distribution c. excretion 4. Dosimetry
C. Contraindications and
adverse reactions 1. Physical conditions 2. Interfering studies 3. Precautions 4. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Image formatting 6. Pitfalls G. Interpretation of images
1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XXIV. Schilling Test A. Indications B. Pharmaceuticals 1. Tracers a. Coblat-57 (Co-57)
labeled B12 b. Co-58 labeled B12 2. Nonradioactive
components a. Vitamin B12 b. Intrinsic factor 3. Dose range and route of
administration 4. Biorouting
a. uptake b. distribution c. excretion 5. Dosimetry
C. Contraindications and
adverse reactions 1. Physical and pathologic
conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Data processing 4. Pitfalls G. Interpretation of data 1. Normal range 2. Normal variants 3. Abnormal 4. Sources of error 5. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XXV. Plasma volume A. General principles of
dilution tests 1. preparing standard
solutions (dilutions) 2. dilution principle
applied to blood volumes B. Indications C. Radiopharmaceuticals 1. I-125 RISA (radioiodinated serum albumin) 2. Dose range and route of
administration 3. Biorouting
a. distribution b. excretion 4. Dosimetry
D. Contraindications and
adverse reactions 1. Physical and pathologic
conditions 2. Interfering studies 3. Precautions 4. Adverse reactions E. Patient preparation F. Equipment G. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Data processing 4. Pitfalls H. Interpretation of data 1. Normal range
calculations 2. Normal variants 3. Abnormal 4. Sources of error 5. Diagnostic/Prognostic
Value of Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XXVI. Red cell mass A. Indications B. Radiopharmaceuticals 1. Chromium-51 (Cr-51)
sodium chromate tagged red blood cells 2. Dose range and route of
administration 3. Biorouting
a. distribution b. excretion 4. Dosimetry
C. Contraindications and
adverse reactions 1. Physical and pathologic
conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Data processing 4. Pitfalls G. Interpretation of data 1. Normal range
calculations 2. Normal variants 3. Abnormal 4. Sources of error 5. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XXVII. Total blood volume A. Indications B. Calculation from plasma
volume and red cell mass C. Interpretation of data 1. Normal range
calculations 2. Normal variant 3. Abnormal 4. Sources of error 5. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XXVIII. Red cell survival
and sequestration A. Indications B. Radiopharmaceuticals 1. Cr-51 sodium chromate
tagged red blood cells 2. Dose range and route of
administration 3. Biorouting
a. uptake b. distribution c. excretion 4. Dosimetry
C. Contraindications and
adverse reactions 1. Physical and pathologic
conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimator 3. computer 4. uptake probe F. Basic procedure and
processing 1. Protocols 2. Dose range and
administration technique 3. Data processing 4. Pitfalls G. Interpretation of data 1. Normal value 2. Normal variants 3. Abnormal 4. Sources of error 5. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis XXIX. Selective spleen
imaging A. Indications B. Radiopharmaceuticals 1. denatured Cr-51 tagged
red blood cells 2. Dose range and route of
administration 3. Biorouting
a. uptake b. distribution c. excretion 4. Dosimetry
C. Contraindications and
adverse reactions 1. Physical and pathologic
conditions 2. Interfering studies 3. Precautions 4. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and
processing 1. Protocol 2. Dose range and
administration technique 3. Acquisition parameters 4. Positioning and views,
including adaptations 5. Image formatting 6. Pitfalls G. Interpretation of images
1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic
Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors
based on diagnosis |
|
|